Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (19161)	3/1/1999 8:25:00 AM
From: DaiS	Read Replies (1) \| Respond to of 23519

BigK, Vivus is a small company selling one ED product essentially. Thus I think discussion of ED in general and all other ED products is relevant when discussing Vivus and its products and its future. As an example, whether or not viagra sales impact Vivus stock price is just one of a multitude of unanswered relevant questions, about which there could be disagreement on the board. DaiS PS What's up with Zebra? It is easy to cut viagra in half approximately. But I still don't have an answer to my question to you!

To: BigKNY3 who wrote (19161)	3/4/1999 10:24:00 PM
From: BigKNY3	Respond to of 23519

Zebra <<First of all, this is not the Viagra Board.>> Dr. Z: As noted before, there are almost as many posts placed by VVUSers on this Board concerning Viagra than MUSE! In the current environment and almost one year after its launch, I believe any future Viagra negative news will have no impact on the price of VVUS. If you have any doubt, just review the price of VVUS on these milestone dates: 11/24/98 (Revised Viagra labeling and update of the FDA Website)and 1/2/99 (Issuance of the ACC/AHA Expert Consensus Report). Moreover, no one has ever proven that negative Viagra news has ever moved the price of VVUS for more than a day. VVUS will only recover if actions are taken that will significantly increase Rx specification in the US... Important trend data that is closely followed by all institutional investors and mutual funds. Note: A weekly report on major Pharma products is available at the Merrill Lynch Research Website by typing in the ticker of any Big Pharma. askmerrill.com BigKNY3